| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/11/2022 | 227.1% | Raymond James | $4 → $3.5 | Maintains | Outperform |
| 08/19/2022 | 273.83% | BTIG | $7 → $4 | Maintains | Buy |
| 08/19/2022 | 273.83% | Raymond James | $7 → $4 | Maintains | Outperform |
| 05/12/2022 | 1208.41% | Ladenburg Thalmann | $15.25 → $14 | Maintains | Buy |
| 05/12/2022 | 554.21% | Raymond James | $9 → $7 | Maintains | Outperform |
| 03/11/2022 | 741.12% | Raymond James | $13 → $9 | Maintains | Outperform |
| 11/15/2021 | 1769.16% | Evercore ISI Group | → $20 | Initiates Coverage On | → Outperform |
| 10/25/2021 | 1114.95% | Raymond James | → $13 | Initiates Coverage On | → Outperform |
LumiraDx Questions & Answers
The latest price target for LumiraDx (NASDAQ: LMDX) was reported by Raymond James on November 11, 2022. The analyst firm set a price target for $3.50 expecting LMDX to rise to within 12 months (a possible 227.10% upside). 7 analyst firms have reported ratings in the last year.
The latest analyst rating for LumiraDx (NASDAQ: LMDX) was provided by Raymond James, and LumiraDx maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LumiraDx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LumiraDx was filed on November 11, 2022 so you should expect the next rating to be made available sometime around November 11, 2023.
While ratings are subjective and will change, the latest LumiraDx (LMDX) rating was a maintained with a price target of $4.00 to $3.50. The current price LumiraDx (LMDX) is trading at is $1.07, which is out of the analyst's predicted range.
